Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients

Cytometry Part B - Clinical Cytometry - United States
doi 10.1002/cyto.b.21527
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

JAMA Neurology
Neurology
2013English

Natalizumab Treatment in Multiple Sclerosis

Clinical Neurology
Neurology
2015English

Natalizumab-Associated Progressive Multifocal Leukoencephalopathy in Patients With Multiple Sclerosis: A Mini Review

Cureus
2018English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

JC Virus Persistence Following Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients Treated With Natalizumab

Annals of Neurology
Neurology
2010English

Predictors for Multiple Sclerosis Relapses After Switching From Natalizumab to Fingolimod

Multiple Sclerosis
Neurology
2014English

Alemtuzumab Following Natalizumab in Highly Active Paediatric-Onset Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Stem Cell Therapy in Patients With Multiple Sclerosis

Multiple Sclerosis
Neurology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy